MyFinsight
Home
Blog
About
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$2,925K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Aggregate gross proceeds
Represents proceeds from issuanc...
Increase (decrease) in accounts ...
Others
Negative Cash Flow Breakdown
Net loss
Non-cash financial expenses
Issuance costs related to warran...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,551
-2,733
-4,412
-3,262
Depreciation
3
2
3
4
Share-based payment arrangement, noncash expense
197
345
38
38
Represent the amount of non cash loss upon entering transactions
-
-
0
-
Non-cash financial expenses
135
-4
-50
-294
Loss (gain) on disposal of property and equipment
-
-
0
-
Loss from lease termination
-
-
0
0
Decrease (increase) in prepaid expenses
-157
959
-1,169
56
Increase in other current assets
15
47
2
-16
Increase (decrease) in accounts payable, trade
268
125
-159
254
Increase (decrease) in operating lease liability
-7
-4
-4
-2
Increase (decrease) in employee related liabilities
68
-319
158
93
Increase (decrease) in accrued liabilities
-
-
102
-
Increase (decrease) in other accounts payable and accrued liabilities
90
-19
-
88
Net cash provided by (used in) operating activities
-2,925
-3,646
-3,016
-2,843
Investment in long-term deposits
1
-
5
-
Purchase of property and equipment
0
0
2
0
Net cash provided by (used in) investing activities
-1
0
-7
0
Represents the amount of prepaid of issuance cost related to at the market offering
-
-
43
31
Aggregate gross proceeds
1,988
83
-
0
Proceeds from stock options exercised
-
-
0
-
Cash acquired in excess of payments to acquire business
-
-
0
0
Payment and prepayment of issuance costs related to at-the-market sales agreement
121
-
-
-
Represents proceeds from issuance of ordinary shares upon public offering
0
0
0
6,000
Proceeds from issuance initial public offering
0
0
-132
-653
Proceeds from warrant exercises
0
0
0
1,780
Represents proceeds from issuance of ordinary shares upon warrants inducement
998
0
0
1,760
Issuance costs related to warrants inducement transaction
125
0
46
232
Represent the value of payment of underwriters promissory note
0
0
1,392
0
Net cash provided by (used in) financing activities
2,740
83
-221
8,624
Cash, cash equivalents, restricted cash, and restricted cash equivalents, period increase (decrease), excluding exchange rate effect
-186
-3,563
-3,244
5,781
Effect of exchange rate on cash, cash equivalents, restricted cash, and restricted cash equivalents, continuing operations
8
-14
-5
3
Balance of cash, cash equivalents and restricted cash at end of period
2,498
6,075
9,324
1,270
Balance of cash, cash equivalents and restricted cash at end of period
2,320
-
-
-
Balance of cash, cash equivalents and restricted cash at end of period
2,320
2,498
6,075
9,324
Cash equivalents, at carrying value
2,229
-
-
-
Restricted cash
91
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Aggregate gross proceeds
$1,988K
Represents proceeds from
issuance of ordinary...
$998K
(-69.54%↓ Y/Y)
Net cash provided by
(used in) financing...
$2,740K
(-62.14%↓ Y/Y)
Canceled cashflow
$246K
Cash, cash
equivalents, restricted...
-$186K
(-108.19%↓ Y/Y)
Canceled cashflow
$2,740K
Increase (decrease) in
accounts payable, trade
$268K
(213.08%↑ Y/Y)
Share-based payment
arrangement, noncash expense
$197K
(239.66%↑ Y/Y)
Decrease (increase) in
prepaid expenses
-$157K
(-121.90%↓ Y/Y)
Increase (decrease) in
other accounts...
$90K
(169.77%↑ Y/Y)
Increase (decrease) in
employee related...
$68K
(585.71%↑ Y/Y)
Depreciation
$3K
(-57.14%↓ Y/Y)
Issuance costs related to
warrants inducement...
$125K
(-72.94%↓ Y/Y)
Payment and prepayment
of issuance costs...
$121K
Net cash provided by
(used in) operating...
-$2,925K
(41.03%↑ Y/Y)
Canceled cashflow
$783K
Net cash provided by
(used in) investing...
-$1K
(85.71%↑ Y/Y)
Net loss
-$3,551K
(16.21%↑ Y/Y)
Non-cash financial
expenses
$135K
Increase in other current
assets
$15K
(1400.00%↑ Y/Y)
Increase (decrease) in
operating lease liability
-$7K
(-800.00%↓ Y/Y)
Investment in long-term
deposits
$1K
Buy us a coffee